Market Overview

Titan Spine Appoints Brian Burke as Chief Operating Officer

Share:

Mr. Burke brings innovative, dynamic approach to leading highly
effective sales organizations

Titan Spine, a medical device surface technology company focused on
developing innovative spinal interbody fusion implants, today announced
the appointment of Brian Burke as Chief Operating Officer (COO). In his
role, Mr. Burke will have broad cross-functional responsibility for the
Company's main business functions of sales, marketing, operations,
hospital contracting, research and development, human resources, and
legal, all to further support the growth of the Company and adoption of
its nanoLOCK® surface technology.

nanoLOCK® is the company's next-generation surface technology
featuring enhanced micro and nano-scaled architecture, proven to
significantly improve the osteogenic response it creates.1

Peter Ullrich, MD, Chief Executive Officer of Titan Spine, commented,
"As we continue to focus on growth, we identified a need to bring on
additional executive talent to the Titan Spine team. Brian has extensive
experience driving effective and dynamic functional leadership, brings a
wealth of experience in the medtech industry working with both privately
and publicly held companies, and has demonstrated a proven track record
of implementing operational efficiency. We welcome Brian and believe he
will be instrumental in expanding Titan's strategic positioning in the
marketplace."

Prior to joining Titan Spine, Mr. Burke served as General Manager for
Zimmer Biomet Dental in North America where he successfully led the
integration of commercial sales and marketing in the United States and
Canada following the $13.4B acquisition of Biomet by Zimmer in 2015,
which created the second-largest company in the dental implant and oral
reconstructive surgery market. He was responsible for leading all North
American sales channels that encompassed direct sales, inside sales, and
specialty sales. Before Zimmer Biomet, Brian was Group Director of Latin
America and Asia for Biomet 3i, where he managed all sales and marketing
activities while also managing regulatory compliance and in-country
manufacturing in specific global areas.

Titan Spine offers a full line of Endoskeleton® titanium
implants that feature its proprietary nanoLOCK® surface
technology, which was launched in the U.S. in October 2016 following FDA
clearance in late 2014. The nanoLOCK® surface technology
consists of a unique combination of roughened topographies at the macro,
micro, and nano levels (MMN™). This unique combination of surface
topographies is designed to create an optimal host-bone response and
actively participate in the fusion process by promoting the upregulation
of osteogenic and angiogenic factors necessary for bone growth,
encouraging natural production of bone morphogenetic proteins (BMPs),
downregulating inflammatory factors, and creating the potential for a
faster and more robust fusion.2,3,4 All Endoskeleton®
devices are covered by the company's risk share warranty.

About Titan Spine
Titan Spine,
LLC is a surface technology company focused on the design and
manufacture of interbody fusion devices for the spine. The company is
committed to advancing the science of surface engineering to enhance the
treatment of various pathologies of the spine that require fusion. Titan
Spine, located in Mequon, Wisconsin and Laichingen, Germany, markets a
full line of Endoskeleton® interbody devices featuring its
proprietary textured surface in the U.S., portions of Europe, and
Australia through its sales force and a network of independent
distributors. To learn more, visit www.titanspine.com.

1 Olivares-Navarrete, R., Hyzy S.L., Gittens, R.A., Berg,
M.E., Schneider, J.M., Hotchkiss, K., Schwartz, Z., Boyan, B. D.
Osteoblast lineage cells can discriminate microscale topographic
features on titanium-aluminum-vanadium surfaces. Ann Biomed Eng.
2014 Dec; 42 (12): 2551-61.

2 Olivares-Navarrete, R., Hyzy, S.L., Slosar, P.J.,
Schneider, J.M., Schwartz, Z., and Boyan, B.D. (2015). Implant materials
generate different peri-implant inflammatory factors: PEEK promotes
fibrosis and micro-textured titanium promotes osteogenic factors. Spine,
Volume 40, Issue 6, 399–404.

3 Olivares-Navarrete, R., Gittens, R.A., Schneider, J.M.,
Hyzy, S.L., Haithcock, D.A., Ullrich, P.F., Schwartz, Z., Boyan, B.D.
(2012). Osteoblasts exhibit a more differentiated phenotype and
increased bone morphogenetic production on titanium alloy substrates
than poly-ether-ether-ketone. The Spine Journal, 12, 265-272.

4 Olivares-Navarrete, R., Hyzy, S.L., Gittens, R.A.,
Schneider, J.M., Haithcock, D.A., Ullrich, P.F., Slosar, P. J.,
Schwartz, Z., Boyan, B.D. (2013). Rough titanium alloys regulate
osteoblast production of angiogenic factors. The Spine Journal,
13, 1563-1570.

View Comments and Join the Discussion!